Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sanofi's ...

Before Merilog, the FDA has given the go-ahead to two biosimilars of Sanofi's basal insulin product Lantus (insulin glargine) – Viatris' Semglee and Eli Lilly's Rezvoglar – which are used to ...